ScripThe end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D
ScripJust a month after expressing “substantial doubt regarding its ability to continue as a going concern,” DBV Technologies shares are soaring on the news that the French firm has reached agreement with
Pink SheetThe US Food and Drug Administration’s vaccines advisory committee now will handle allergenic products following the termination of a panel created 40 years ago to deal with the rarely seen application
ScripThe news that Novartis AG has terminated a late-stage peanut allergy trial of one of its more closely watched assets, ligelizumab, looks like good news for other players in the space, notably DBV T